Is the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) associated with an increased risk of sight-threatening diabetic retinopathy (DR) or nonarteritic anterior ischemic optic neuropathy (NAION)? The gene discussed is GCG; the disease is type 2 diabetes mellitus.